Hospital de Cruces-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2024

  1. CircRNAome of Childhood Acute Lymphoblastic Leukemia: Deciphering Subtype-Specific Expression Profiles and Involvement in TCF3::PBX1 ALL

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification

    Acta Neuropathologica, Vol. 145, Núm. 5, pp. 651-666

  2. microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma

    Scientific reports, Vol. 13, Núm. 1, pp. 12159

2022

  1. Identification and Functional Analysis of a Novel CTNNB1 Mutation in Pediatric Medulloblastoma

    Cancers, Vol. 14, Núm. 2

2020

  1. Role of rs10406069 in miR-5196 in hyperdiploid childhood acute lymphoblastic leukemia

    Epigenomics, Vol. 12, Núm. 22, pp. 1949-1955

  2. Variability in Cerebrospinal Fluid MicroRNAs Through Life

    Molecular Neurobiology, Vol. 57, Núm. 10, pp. 4134-4142

2019

  1. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review

    Critical Reviews in Oncology/Hematology, Vol. 139, pp. 7-15

  2. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 19, Núm. 6, pp. 564-569

2018

  1. Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk

    Oncotarget, Vol. 9, Núm. 33, pp. 22907-22914

  2. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment

    Pharmacogenomics, Vol. 19, Núm. 18, pp. 1403-1412

  3. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 18, Núm. 6, pp. 704-712

  4. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: Involvement of miRNA polymorphisms in hepatotoxicity

    Epigenomics, Vol. 10, Núm. 4, pp. 409-417

  5. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 19, Núm. 4, pp. 361-373

2017

  1. Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population

    PLoS ONE, Vol. 12, Núm. 5

2016

  1. Lack of association of the CEP72 RS924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population

    Pharmacogenetics and Genomics, Vol. 26, Núm. 2, pp. 100-102

  2. MIR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenetics and Genomics, Vol. 26, Núm. 11, pp. 517-525

  3. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 17, Núm. 7, pp. 731-741

2014

  1. Methylation of the nonhomologous end joining repair pathway genes does not explain the increase of translocations with aging

    Age, Vol. 36, Núm. 6

  2. Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility

    Pediatric Research, Vol. 75, Núm. 6, pp. 767-773

2011

  1. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia

    Pediatric Blood and Cancer, Vol. 57, Núm. 4, pp. 612-619